Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313302236> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4313302236 endingPage "1458" @default.
- W4313302236 startingPage "1451" @default.
- W4313302236 abstract "GRP78 overexpression in myeloma cells has been associated with bortezomib resistance in multiple myeloma (MM). However, serum GRP78 as a maker of bortezomib-based treatment response remains unexplored. The objective of the study was to evaluate serum GRP78 levels in MM patients who underwent a bortezomib-based induction regimen. This cross-sectional study included adult MM patients (n=30) who completed at least four cycles of bortezomib-based induction therapy. Healthy volunteers (n=30) and newly diagnosed MM patients (n=19) were also recruited to identify the disease-associated change in GRP78 levels. Serum GRP78 was estimated by ELISA. Surface and intracellular expression of GRP78 in bone marrow plasma cells was evaluated in ten MM patients by flow cytometry. Among 30 MM patients [median (range): 52 (38-68) years; 20 males] who completed at least four cycles of bortezomib-based induction therapy, 20 were responders and 10 were non-responders. Serum GRP78 levels were not significantly different between responders [median (IQR): 5.2 (3.1, 8.0) μg/ml] and non-responders [median (IQR): 4.3 (0.1, 7.1) μg/ml] (p=0.4). Although non-significant (p=0.3), median serum GRP78 was higher in newly diagnosed patients when compared to healthy volunteers. Bone marrow plasma cells ranged from 0.2 to 57.8% in the analyzed samples. Intracellular GRP78 expression in bone marrow plasma cells was higher (1.6 to 5 times) when compared to surface expression. To conclude, serum GRP78 levels vary widely in different MM patient groups but did not correlate with response to a bortezomib-based induction regimen." @default.
- W4313302236 created "2023-01-06" @default.
- W4313302236 creator A5016541448 @default.
- W4313302236 creator A5032576109 @default.
- W4313302236 creator A5051492143 @default.
- W4313302236 creator A5052691457 @default.
- W4313302236 creator A5076526964 @default.
- W4313302236 creator A5076993473 @default.
- W4313302236 creator A5078468695 @default.
- W4313302236 date "2022-01-01" @default.
- W4313302236 modified "2023-09-30" @default.
- W4313302236 title "Evaluation of serum glucose-regulated protein 78 (GRP78) as a biomarker of treatment response to bortezomib-based induction regimen in multiple myeloma: A cross-sectional pilot study" @default.
- W4313302236 doi "https://doi.org/10.4149/neo_2022_220526n564" @default.
- W4313302236 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36591800" @default.
- W4313302236 hasPublicationYear "2022" @default.
- W4313302236 type Work @default.
- W4313302236 citedByCount "0" @default.
- W4313302236 crossrefType "journal-article" @default.
- W4313302236 hasAuthorship W4313302236A5016541448 @default.
- W4313302236 hasAuthorship W4313302236A5032576109 @default.
- W4313302236 hasAuthorship W4313302236A5051492143 @default.
- W4313302236 hasAuthorship W4313302236A5052691457 @default.
- W4313302236 hasAuthorship W4313302236A5076526964 @default.
- W4313302236 hasAuthorship W4313302236A5076993473 @default.
- W4313302236 hasAuthorship W4313302236A5078468695 @default.
- W4313302236 hasBestOaLocation W43133022361 @default.
- W4313302236 hasConcept C126322002 @default.
- W4313302236 hasConcept C203014093 @default.
- W4313302236 hasConcept C2776364478 @default.
- W4313302236 hasConcept C2777478702 @default.
- W4313302236 hasConcept C2780007613 @default.
- W4313302236 hasConcept C2781413609 @default.
- W4313302236 hasConcept C553184892 @default.
- W4313302236 hasConcept C71924100 @default.
- W4313302236 hasConcept C90924648 @default.
- W4313302236 hasConceptScore W4313302236C126322002 @default.
- W4313302236 hasConceptScore W4313302236C203014093 @default.
- W4313302236 hasConceptScore W4313302236C2776364478 @default.
- W4313302236 hasConceptScore W4313302236C2777478702 @default.
- W4313302236 hasConceptScore W4313302236C2780007613 @default.
- W4313302236 hasConceptScore W4313302236C2781413609 @default.
- W4313302236 hasConceptScore W4313302236C553184892 @default.
- W4313302236 hasConceptScore W4313302236C71924100 @default.
- W4313302236 hasConceptScore W4313302236C90924648 @default.
- W4313302236 hasIssue "06" @default.
- W4313302236 hasLocation W43133022361 @default.
- W4313302236 hasLocation W43133022362 @default.
- W4313302236 hasOpenAccess W4313302236 @default.
- W4313302236 hasPrimaryLocation W43133022361 @default.
- W4313302236 hasRelatedWork W1972519999 @default.
- W4313302236 hasRelatedWork W1984437179 @default.
- W4313302236 hasRelatedWork W2022680061 @default.
- W4313302236 hasRelatedWork W2089743544 @default.
- W4313302236 hasRelatedWork W2273587585 @default.
- W4313302236 hasRelatedWork W2605580960 @default.
- W4313302236 hasRelatedWork W3134875278 @default.
- W4313302236 hasRelatedWork W4241469660 @default.
- W4313302236 hasRelatedWork W4248694421 @default.
- W4313302236 hasRelatedWork W4313857557 @default.
- W4313302236 hasVolume "69" @default.
- W4313302236 isParatext "false" @default.
- W4313302236 isRetracted "false" @default.
- W4313302236 workType "article" @default.